Recent coverage has highlighted that Orthocell\u2019s flagship nerve repair product, Remplir\u2122, is expected to be exempt from newly proposed US tariffs targeting pharmaceutical imports.<\/p>\n
While seemingly a technical detail, the outcome reinforces a key advantage of Remplir\u2019s positioning \u2013 its classification as a medical device rather than a pharmaceutical product.<\/p>\n
Orthocell Managing Director Paul Anderson said:<\/p>\n
\u201cThe exemption ensures that Remplir remains competitively positioned in the US as we continue to execute on our growth strategy. This outcome supports our mission to deliver effective nerve repair solutions to patients and surgeons without disruption.\u201d<\/em><\/p>\n